CA2873143A1 - Radio-pharmaceutical complexes - Google Patents

Radio-pharmaceutical complexes Download PDF

Info

Publication number
CA2873143A1
CA2873143A1 CA 2873143 CA2873143A CA2873143A1 CA 2873143 A1 CA2873143 A1 CA 2873143A1 CA 2873143 CA2873143 CA 2873143 CA 2873143 A CA2873143 A CA 2873143A CA 2873143 A1 CA2873143 A1 CA 2873143A1
Authority
CA
Canada
Prior art keywords
tissue
complex
moieties
moiety
targeting moiety
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2873143
Other languages
English (en)
French (fr)
Inventor
Hanne Therese BONGE-HANSEN
Olav Benjamin RYAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AS
Original Assignee
Algeta ASA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Algeta ASA filed Critical Algeta ASA
Publication of CA2873143A1 publication Critical patent/CA2873143A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pyridine Compounds (AREA)
CA 2873143 2012-05-11 2013-05-13 Radio-pharmaceutical complexes Abandoned CA2873143A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201208309A GB201208309D0 (en) 2012-05-11 2012-05-11 Complexes
GB1208309.3 2012-05-11
PCT/EP2013/059840 WO2013167755A1 (en) 2012-05-11 2013-05-13 Radio-pharmaceutical complexes

Publications (1)

Publication Number Publication Date
CA2873143A1 true CA2873143A1 (en) 2013-11-14

Family

ID=46458687

Family Applications (3)

Application Number Title Priority Date Filing Date
CA 2873143 Abandoned CA2873143A1 (en) 2012-05-11 2013-05-13 Radio-pharmaceutical complexes
CA2873144A Expired - Fee Related CA2873144C (en) 2012-05-11 2013-05-13 Radio-pharmaceutical complexes
CA2873142A Abandoned CA2873142A1 (en) 2012-05-11 2013-05-13 Radio-pharmaceutical complexes

Family Applications After (2)

Application Number Title Priority Date Filing Date
CA2873144A Expired - Fee Related CA2873144C (en) 2012-05-11 2013-05-13 Radio-pharmaceutical complexes
CA2873142A Abandoned CA2873142A1 (en) 2012-05-11 2013-05-13 Radio-pharmaceutical complexes

Country Status (9)

Country Link
US (3) US20150147272A1 (enExample)
EP (3) EP2846843A1 (enExample)
JP (3) JP6219372B2 (enExample)
KR (3) KR20150092701A (enExample)
CN (3) CN104602716A (enExample)
CA (3) CA2873143A1 (enExample)
GB (1) GB201208309D0 (enExample)
HK (3) HK1207307A1 (enExample)
WO (3) WO2013167754A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2511266B1 (en) 2006-07-10 2019-09-04 The Regents of The University of California Luminescent 1-hydroxy-2-pyridinone chelates of lanthanides
WO2011025790A1 (en) 2009-08-24 2011-03-03 Lumiphore, Inc. Macrocyclic hopo chelators
GB201002508D0 (en) 2010-02-12 2010-03-31 Algeta As Product
GB201208309D0 (en) 2012-05-11 2012-06-27 Algeta As Complexes
US11453652B2 (en) 2013-03-15 2022-09-27 Lumiphore, Inc. Di-macrocycles
MA41176A (fr) * 2014-12-17 2017-10-24 Bayer As Complexes radio-pharmaceutiques
US10821195B2 (en) * 2015-09-10 2020-11-03 Memorial Sloan Kettering Cancer Center Compositions for therapeutics, targeted PET imaging and methods of their use
GB201600154D0 (en) * 2016-01-05 2016-02-17 Bayer As Isotope preparation method
GB201600158D0 (en) * 2016-01-05 2016-02-17 Bayer As Purification method
EP3432936A1 (en) 2016-03-24 2019-01-30 Bayer Pharma Aktiengesellschaft Radio-pharmaceutical complexes
CR20180581A (es) 2016-06-10 2019-02-11 Bayer Pharma AG Complejos radio-farmacéuticos
WO2018153975A1 (en) * 2017-02-24 2018-08-30 Bayer As Combination therapy comprising a radiopharmaceutical and a dna-repair inhibitor
US20210017277A1 (en) * 2018-03-14 2021-01-21 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Anti-cd33 chimeric antigen receptors and their uses
US20210187134A1 (en) 2018-08-28 2021-06-24 Bayer As Combination of pi3k-inhibitors and targeted thorium conjugates
KR20210116437A (ko) * 2018-11-20 2021-09-27 코넬 유니버시티 방사성핵종의 마크로사이클릭 복합체 및 암의 방사선 요법에서의 이의 용도
USD885822S1 (en) 2018-12-14 2020-06-02 Whirlpool Corporation Food grinder
WO2020169537A1 (en) 2019-02-21 2020-08-27 Bayer Aktiengesellschaft Combination of pd-1/pd-l1 inhibitors and targeted thorium conjugates
WO2020169538A1 (en) 2019-02-22 2020-08-27 Bayer Aktiengesellschaft Combination of ar antagonists and targeted thorium conjugates
AR119479A1 (es) 2019-07-25 2021-12-22 Bayer As Radiofármacos dirigidos para diagnóstico y tratamiento de cáncer
WO2021142258A1 (en) * 2020-01-10 2021-07-15 Fusion Pharmaceuticals Inc. Macrocyclic chelates and uses thereof
CN115916731A (zh) * 2020-01-23 2023-04-04 瑞德兰有限责任公司 用于制备定制的放射性同位素溶液的系统和方法
US20240000838A1 (en) * 2020-11-30 2024-01-04 Simcere Innovation, Inc. Universal chimeric antigen receptor-expressing immune cells for allogeneic cell therapy
CN116745323A (zh) 2021-01-22 2023-09-12 拜耳股份有限公司 Lrrc15抗体及其缀合物
JPWO2025058000A1 (enExample) 2023-09-13 2025-03-20

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4698431A (en) * 1985-11-12 1987-10-06 The United States Of America As Represented By The United States Department Of Energy Hydroxypyridonate chelating agents
US5624901A (en) * 1994-04-15 1997-04-29 The Regents Of The University Of California 3-hydroxy-2(1H)-pyridinone chelating agents
US8383081B2 (en) * 1999-05-10 2013-02-26 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods of use
NO312708B1 (no) 2000-02-21 2002-06-24 Anticancer Therapeutic Inv Sa Radioaktive liposomer til terapi
NO313180B1 (no) 2000-07-04 2002-08-26 Anticancer Therapeutic Inv Sa Bensökende alfapartikkel emitterende radiofarmasöytika
GB0308731D0 (en) 2003-04-15 2003-05-21 Anticancer Therapeutic Inv Sa Method of radiotherapy
EP1763372B1 (en) * 2004-06-25 2016-11-30 The European Union, represented by the European Commission Radionuclides for medical use
US7794691B2 (en) * 2004-06-25 2010-09-14 The European Community, Represented By The European Commission Radionuclides for medical use
WO2008063721A2 (en) 2006-08-15 2008-05-29 The Regents Of The University Of California Luminescent macrocyclic lanthanide complexes
US8158804B2 (en) 2007-01-11 2012-04-17 Ge Healthcare As Chelating agents
JP5985392B2 (ja) * 2009-07-22 2016-09-06 アクティニウム ファーマシューティカルズ インコーポレイテッド 放射性免疫複合体を生成するための方法
JP2013515744A (ja) * 2009-12-24 2013-05-09 ルミフォア，インコーポレイテッド 放射性医薬品錯体
GB201002508D0 (en) * 2010-02-12 2010-03-31 Algeta As Product
EP2359802B1 (en) * 2010-02-12 2014-06-18 Evonik Degussa GmbH Cosmetic composition containing polyglycerol partial ester
GB201208309D0 (en) 2012-05-11 2012-06-27 Algeta As Complexes

Also Published As

Publication number Publication date
CA2873144C (en) 2021-03-16
US20150147272A1 (en) 2015-05-28
EP2846843A1 (en) 2015-03-18
CN104540530A (zh) 2015-04-22
JP2015517482A (ja) 2015-06-22
EP2846844B1 (en) 2020-04-01
US20150110817A1 (en) 2015-04-23
KR20150092700A (ko) 2015-08-13
WO2013167756A1 (en) 2013-11-14
KR20150092702A (ko) 2015-08-13
US20150104385A1 (en) 2015-04-16
HK1206981A1 (en) 2016-01-22
JP6211066B2 (ja) 2017-10-11
CN104602716A (zh) 2015-05-06
WO2013167754A1 (en) 2013-11-14
JP2015523326A (ja) 2015-08-13
JP6219372B2 (ja) 2017-10-25
WO2013167755A1 (en) 2013-11-14
HK1207307A1 (zh) 2016-01-29
EP2846844A1 (en) 2015-03-18
HK1206982A1 (en) 2016-01-22
CA2873142A1 (en) 2013-11-14
GB201208309D0 (en) 2012-06-27
EP2846842A1 (en) 2015-03-18
US9827336B2 (en) 2017-11-28
JP2015517483A (ja) 2015-06-22
CN104619355A (zh) 2015-05-13
CA2873144A1 (en) 2013-11-14
KR20150092701A (ko) 2015-08-13

Similar Documents

Publication Publication Date Title
CA2873144C (en) Radio-pharmaceutical complexes
US10682430B2 (en) Alpha-emitting complexes
AU2021202665B2 (en) Radio-pharmaceutical complexes

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20190514